FOLH1 and prostate carcinoma: To date, the most extensively investigated TAAs preclinically and clinically in the context of prostate cancer are prostate stem cell antigen (PSCA), epithelial cell adhesion molecule (EpCAM) and prostate-specific membrane antigen (PSMA).